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The purine nucleoside adenosine is present in all cells in tightly regulated concentrations. It is released under a variety of
physiological and pathophysiological conditions to facilitate protection and regeneration of tissues. Adenosine acts via specific
GPCRs to either stimulate cyclic AMP formation, as exemplified by Gs-protein-coupled adenosine receptors (A2A and A2B), or
inhibit AC activity, in the case of Gi/o-coupled adenosine receptors (A1 and A3). Recent advances in our understanding of GPCR
structure have provided insights into the conformational changes that occur during receptor activation following binding of
agonists to orthosteric (i.e. at the same binding site as an endogenous modulator) and allosteric regulators to allosteric sites
(i.e. at a site that is topographically distinct from the endogenous modulator). Binding of drugs to allosteric sites may lead to
changes in affinity or efficacy, and affords considerable potential for increased selectivity in new drug development. Herein,
we provide an overview of the properties of selective allosteric regulators of the adenosine A1 and A3 receptors, focusing on
the impact of receptor dimerization, mechanistic approaches to single-cell ligand-binding kinetics and the effects of A1- and
A3-receptor allosteric modulators on in vivo pharmacology.
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Introduction
Adenosine is a reactive metabolite that has a major role in
regulating a number of physiological and pathological pro-
cesses, including inflammation, pain, hypoxia and cardiovas-
cular regulation (Fredholm et al., 2011). Adenosine acts via
four specific GPCRs, which have been denoted as adenosine
A1, A2A, A2B and A3 receptors (Alexander et al., 2013; Fredholm
et al., 2011). The A1 and A3 receptors preferentially couple to
Gi/o proteins and have an inhibitor action on AC activity,
while the A2A and A2B receptors couple to Gs proteins and
stimulate cyclic AMP formation (Jacobson, 2009; Fredholm
et al., 2011; Muller and Jacobson, 2011). The crystal structure
of the A2A receptor in both antagonist (Jaakola et al., 2008)
and agonist (Xu et al., 2011) bound conformations has
recently been solved. Numerous selective agonists and
antagonists for each adenosine receptor subtype are now
available for the study of receptor function (reviewed in
Jacobson, 2009; Fredholm et al., 2011; Muller and Jacobson,
2011). In the case of the Gi/o-coupled adenosine receptors (A1
and A3) reviewed here, a number of compounds are undergo-
ing evaluation for disease indications (Muller and Jacobson,
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2011). These include A1-receptor partial agonists (e.g.
capadenoson, selodenoson and tecadenoson) for paroxysmal
supraventricular tachycardia, atrial fibrillation and angina
pectoris, and A3-receptor agonists (e.g. CF101, CF102) for
inflammatory disease, glaucoma and cancer (Bar-Yehuda
et al., 2011; Cohen et al., 2011; Muller and Jacobson, 2011;
Albrecht-Kupper et al., 2012; Tendera et al., 2012).
Activation of cell surface adenosine receptors by endog-
enous adenosine requires it to be available at the extracellular
surface of cells. Extracellular adenosine can rise as a conse-
quence of several pathways (Fredholm et al., 2011). It can be
formed intracellularly following various metabolic processes
and be exported from cells via membrane transporters, or it
can be formed in the extracellular space from adenine nucleo-
tides released from cells. Once ATP or ADP is released, the
nucleotide is broken down by nucleoside triphosphate
diphosphohydrolases (e.g. CD39) and then ecto-5′-
nucleotidase (CD73) to adenosine (Fredholm et al., 2011;
Knapp et al., 2012). It is well known that neurons and plate-
lets can store and release ATP and ADP, respectively, in
response nerve stimulation and platelet activation. However,
more recently, there has been a growing awareness that the
intracellular second messenger cyclic AMP may also be a
source of extracellular adenosine in many cell types. Thus,
intracellular cyclic AMP can be released from cells in response
to receptor stimulation (McCrea and Hill, 1993; Baker et al.,
2004) and it is known that extracellular cyclic AMP can be
rapidly converted to adenosine via the action of ecto-
phosphodiesterase and ecto-5′-nucleotidase (Dubey et al.,
2001; Chiavegatta et al., 2008; Goedeke, 2008).
The intricacies of localized extracellular release of adenine
nucleotides and subsequent production of adenosine follow-
ing CD73 activity has recently provided insights into the role
of adenosine A1 receptors in mediating localized analgesia in
animals and humans (Goldman et al., 2010; Sowa et al., 2010;
Street and Zylka, 2011). Thus, there is evidence that localized
A1-receptor activation may underlie the antinociceptive
effects of acupuncture as manual stimulation of acupuncture
needles can result in localized release of adenine nucleotides
and adenosine formation, leading to an analgesia that can be
mimicked by an A1-receptor agonist (Goldman et al., 2010).
Furthermore, intrathecal application of recombinant CD73
(to enhance formation of adenosine) produced a long-lasting
antinociceptive effect that was not observed in adenosine
A1-receptor knockout mice (Sowa et al., 2010). Similarly,
recent work with human neutrophils has highlighted an auto-
crine role for ATP, which is released from the leading edge of
neutrophils during chemotaxis (Chen et al., 2006; Corriden
and Insel, 2012). ATP is then rapidly converted to adenosine,
which then acts via adenosine A3 receptors (recruited to the
leading edge of neutrophils) to promote cell migration (Chen
et al., 2006; Corriden and Insel, 2012; Corriden et al., 2013).
In addition, there is increasing evidence that adenosine A1
and A3 receptors may be involved in promoting angiogenesis
and the release of VEGF in response to local hypoxia and
neoplasia (Clark et al., 2007; Merighi et al., 2009).
The above studies suggest that localized regulation of
adenosine production (e.g. by recombinant CD73), or its
activity at its target adenosine receptor itself (e.g. A1 or A3),
may have important therapeutic implications. One way in
which the activity of endogenous adenosine can be subtly
regulated at the level of its target receptor is via drugs that
bind to an allosteric site on the receptor and act as allosteric
modulators to enhance or inhibit the binding and/or func-
tion of adenosine. Here, we review the properties of various
small-molecule allosteric regulators of the adenosine A1 and
A3 receptors focusing on the impact of receptor dimerization,
mechanistic approaches to single-cell ligand-binding kinetics
and the effects of A1- and A3-receptor allosteric modulators on
in vivo pharmacology.
Allosteric regulation of GPCRs
GPCRs comprise the largest family of transmembrane pro-
teins and represent major targets for drug discovery (Williams
and Hill, 2009; Roth and Marshall, 2012). Considerable
advances in our knowledge of GPCR structure have been
made recently (Jaakola et al., 2008; Chien et al., 2010; Chung
et al., 2011; Rasmussen et al., 2011) and this has led to sig-
nificant insights into the conformational changes that occur
during receptor activation in response to agonists that act at
the same site (orthosteric) as the endogenous hormone or
neurotransmitter (Chung et al., 2011; de Graaf et al., 2011;
Rasmussen et al., 2011). However, over the past decade, there
has been an increasing acceptance that drugs can also bind
to a topographically distinct site (allosteric) on the GPCR
protein and elicit a conformational change that can lead to a
change in the affinity or efficacy of a ligand occupying the
classical orthosteric binding site (Figure 1A; May et al., 2007;
Kenakin, 2009, 2012; Keov et al., 2010). This suggests that
GPCRs are able to bind more than one ligand simultaneously
(i.e. both an allosteric and an orthosteric ligand; May et al.,
2007; Kenakin, 2009, 2012; Keov et al., 2010). Various math-
ematical models have been developed to explain these phe-
nomena, but key features of an allosteric mechanism of
action are that the effect is saturable, can depend on the
specific ligand occupying the orthosteric site (probe depend-
ence) and provides scope for both positive and negative
effects on ligand binding and/or function (May et al., 2007;
Kenakin, 2009, 2012; Keov et al., 2010).
Some of the earliest allosteric modulators were discovered
for the adenosine A1 receptor (Bruns and Fergus, 1990; Bruns
et al., 1990; Göblyös and Ijzerman, 2011; Kimatrai-Salvador
et al., 2012). PD 81,723 has become a reference allosteric
enhancer for the A1 receptor. Early studies demonstrated that
PD 81,723, which has A1-receptor antagonist properties at
high concentrations, was able to increase the binding of an
orthosteric agonist radioligand at lower concentrations of PD
81,723 to enhance the functional activation of the A1 recep-
tor in the brain (Janusz and Berman, 1993) and cardiovascu-
lar tissues (Amoah-Apraku et al., 1993) and to slow down the
dissociation of the agonist radioligand from the A1 receptor
(Bruns and Fergus, 1990; Bruns et al., 1990); the latter effect
being indicative of an allosteric mechanism of action (see
below; May et al., 2007; Keov et al., 2010; Göblyös and
Ijzerman, 2011). Furthermore, recent studies using site-
directed mutagenesis have indicated that the allosteric
binding site for PD 81,723 may reside within extracellular
loop 2 of the adenosine A1 receptor (Peeters et al., 2012).
Selective allosteric enhancers of agonist binding have also
been described for the adenosine A3 receptor (Gao et al., 2001;
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Heitman et al., 2009; Göblyös and Ijzerman, 2011). The
impact of an allosteric modulator is not, however, restricted
to the binding and function of orthosteric agonists. For
example, the food dye Brilliant Black BN is able to act allos-
terically to reduce the affinity of particular adenosine A1- and
A3-receptor antagonists (e.g. xanthine amine congener) for
the orthosteric site without altering the ability of agonists to
interact with these two receptors (May et al., 2010a). This is a
good example of probe dependence where the effect observed
differs, depending on the nature of the ligand occupying the
orthosteric site. In addition to small molecules exerting allos-
teric influences on GPCRs, there is considerable evidence that
sodium ions can also mediate allosteric effects on a range of
GPCRs, including both the adenosine A1 and A3 receptors (Liu
et al., 2012). In the case of A1 and A3 receptors, a highly
conserved aspartate residue in transmembrane region 2 of
each receptor (Asp2,50) has been implicated in the allosteric
actions of sodium ions. Mutation of this residue to alanine or
asparagine largely abolishes the effect (Barbhaiya et al., 1996;
Gao et al., 2003). In a recent high-resolution crystal structure
of the adenosine A2A receptor, the precise location of the
sodium ion and its associated water cluster has been identi-
fied and shown to interact with Asp2,50 (Liu et al., 2012).
Recent studies with imidazoquinolinamine allosteric
enhancers (e.g. LUF5999, LUF6000 and LUF6001) of the
adenosine A3 receptor have shown that they have differing
effects on the affinity and efficacy of a selective A3-agonist
Cl-IB-MECA (Gao et al., 2011). This illustrates the independ-
ence of allosteric actions on binding affinity and efficacy.
Furthermore, the allosteric modulation of orthosteric agonist
efficacy was dependent on the intracellular signalling
response being measured. This suggests that the allosteric
modulation of agonist efficacy may be functionally biased
(Gao et al., 2011). Functional selectivity of orthosteric and
allosteric ligands has also been investigated for the adenosine
A1 receptor (Cordeaux et al., 2004; Valant et al., 2010;
Langemeijer et al., 2013). The magnitude of positive allosteric
modulation of the 2-amino-3-benzoylthiophene adenosine
A1-receptor allosteric enhancer, VCP520, varied between
pathways (Valant et al., 2010). This is an example of an
Figure 1
Schematic representation of allosteric regulation of GPCRs by (A) allosteric ligands, (B) signalling proteins or (C) GPCR dimerization. See text for
further explanation.
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allosteric modulation engendering functional selectivity in
the actions of orthosteric ligands (Valant et al., 2010). These
studies highlight the ability of allosteric ligands to further
‘fine-tune’ orthosteric ligand responses. Signalling bias from
GPCRs is a concept that has developed considerably over the
last few years as knowledge that GPCRs can regulate signal-
ling pathways independently of heterotrimeric G protein has
become available (e.g. β-arrestin pathways; Kenakin, 2012;
Whalen et al., 2011). Thus, it is clear that activation of
β-arrestin pathways are not only associated with desensitiza-
tion and receptor internalization but can also change the
signalling pathways that are activated. Furthermore, specific
agonists appear to be able to direct signalling to different
pathways via the same cell surface receptor. Some of the best
evidence for this has come from the β2-adenoceptor field,
where certain β-blockers (e.g. propranolol) can have an
inverse agonist effect of Gs-mediated signalling pathways, but
an agonist action on MAP kinase (Azzi et al., 2003; Baker
et al., 2003). The concept of biased signalling, however, is a
natural extension of allosterism (Figure 1B). The intracellular
signalling proteins (e.g. heterotrimeric G proteins of
β-arrestin) bind to the GPCR at a site distinct from the orthos-
teric binding site. As a consequence, they can be considered
as allosteric regulators (in this case, proteins) that can have a
reciprocal effect on ligand binding (or coupling in the case of
the protein) and lead to altered affinity and efficacy for par-
ticular agonists (Kenakin, 2012). In many ways, therefore,
biased signalling is a natural consequence of a key feature of
allosterism, namely probe dependence (Figure 1B).
The ability of receptor-associated proteins to act as allos-
teric modulators of ligand binding and efficacy can be
extended to neighbouring receptors that form homo- or
heterodimers or higher order oligomers (Figure 1C). For
example, we have recently provided evidence for negative
cooperativity across the dimer interface of an adenosine
A3-receptor homodimer (May et al., 2011). In this case,
binding of an orthosteric ligand to one protomer (mono-
meric component) of the homomeric complex can markedly
alter the affinity of a ligand binding to the second protomer
(May et al., 2011). Evidence is also accumulating that the
adenosine A1 receptor can form heterodimers with P2Y recep-
tors, adenosine A2A receptors, β1- and β2-adrenoceptors to
influence orthosteric ligand binding and/or intracellular sig-
nalling (Suzuki et al., 2006; Chandrasekera et al., 2013;
Cristovao-Ferreira et al., 2013; Franco et al., 2013). In addi-
tion to partner receptors within oligomeric complexes, other
extracellular proteins can also bind to GPCRs and mediate
allosteric influences. For example, adenosine deaminase
(ADA), which is a key enzyme catalysing the deamination of
adenosine, can be released from cells and bind to cell surface
proteins and act as an ectoenzyme (Gracia et al., 2013). One
of the proteins that bind ADA is the adenosine A1 receptor
(Ciruela et al., 1996; Gracia et al., 2013). The association of
ADA with the adenosine A1 receptor can lead to enhanced
agonist affinity and efficacy (Gracia et al., 2008; 2013). The
consequence of a metabolic enzyme for the endogenous acti-
vator being associated with the cell surface adenosine recep-
tor, which can enhance affinity and efficacy, is therefore
likely to amplify local signalling while limiting the duration
of action (and spread of activity) due to its local metabolic
activity.
Overview of small-molecule allosteric
regulators acting on the adenosine A1
and A3 receptors
The therapeutic potential of allosteric regulators that can
amplify or modulate the local actions of adenosine is clear and
efforts are in progress to develop these reagents for a wide
range of GPCRs. The development of allosteric modulators
targeted at the adenosine receptor family has recently been
comprehensively reviewed (Göblyös and Ijzerman, 2011;
Jacobson et al., 2011). For brevity, we will focus our discussion
on the medicinal chemistry of allosteric modulators specifi-
cally mentioned within this review (Figure 2). As stated
earlier, PD 81,723 was one of the key compounds originally
described in back-to-back papers from the Parke-Davis
Pharmaceutical Research Division (Bruns and Fergus, 1990;
Bruns et al., 1990) recounting the identification of the first
allosteric regulators of adenosine A1-receptor binding. The
chemical series was originally identified from the Parke-Davis
compound bank via a 300-ligand adenosine A1 binding
screen. While the 2-amino-3-benzoylthiophene chemical
scaffolds had been originally synthesized as intermediates for
benzodiazepine-like compounds (Tinney et al., 1974), recog-
nition of their adenosine antagonist activity prompted a more
thorough analysis of this privileged chemical template (Bruns
and Fergus, 1990). From this medicinal chemistry study,
second-generation compounds were unexpectedly found to
increase the specific binding of [3H]N6-cyclohexyladenosine
to rat brain membranes. This, in turn, resulted in the synthesis
of further compounds to identify pertinent structure–activity
relationships and, in so doing, identified PD 81,723 as a key
analogue displaying a significantly improved allosteric profile
(Bruns et al., 1990). This core structure has been further modi-
fied by a number of groups thereby developing a robust
structure activity relationship profile and a series of ligands
with comparable or more favourable allosteric activity (van
der Klein et al., 1999; Kourounakis et al., 2000; Baraldi et al.,
2003, 2004; Nikolakopoulos et al., 2006; Romagnoli et al.,
2008; Valant et al., 2010). One particularly successful manipu-
lation centred on removal of the 4- and 5-methyl groups and
installation of substituted phenyl rings back into these posi-
tions of PD 81,723 (Aurelio et al., 2008). It was interesting to
note that the most efficacious compound possessed no sub-
stituent in the 5-position and this lead to further exploitation
of this observation through the synthesis and evaluation of
the next generation of ligands, which identified VCP520 as a
potent allosteric enhancer of A1-receptor-mediated signalling
(Aurelio et al., 2009).
In a similar fashion as the discovery of PD 81,723, the lead
compounds recognized as allosteric modulators of the adeno-
sine A3 receptor were identified from screening diverse chemi-
cal libraries in binding assays at this receptor subtype
(Jacobson et al., 2011). In this instance, certain lead mol-
ecules were shown to increase the level of binding of [125I]AB-
MECA (Gao et al., 2001; 2002). Key molecular scaffolds that
supported allosteric modulation at the adenosine A3 receptor
were identified as 3-(2-pyridinyl)isoquinolines (e.g. VUF5455)
and 3H-imidazo-[4,5-c]quinolin-4-amines (e.g. LUF5999,
LUF6000 and LUF6001). With regard to the former, further
exploration of the 3-(2-pyridinyl)isoquinoline scaffold
BJPAllosterism at adenosine A1 and A3 receptors
British Journal of Pharmacology (2014) 171 1102–1113 1105
revealed a complex situation where some members were pure
antagonists of the orthosteric binding site, for example,
VUF5455 itself (Heitman et al., 2009), consequently render-
ing them not particularly useful as future therapeutics.
However, the imidazoquinolinamines fared better in this
respect; the original molecule DU124183 (Gao et al., 2002)
was further modified at the 2- and 4-positions and numerous
resultant derivatives displayed potentiation of the maximum
efficacy of Cl-IB-MECA at the A3 receptor (Göblyös et al.,
2006). Indeed, LUF6000 was shown to enhance agonist effi-
cacy in a functional assay and decrease agonist dissociation
rate without influencing agonist potency. This was postulated
to be a result of its experimentally observed decreased
interaction with the orthosteric binding site on the adeno-
sine A3 receptor. As previously mentioned, a more thorough
analysis of this and related ligands (LUF5999 and LUF6001)
identified that these imidazoquinolinamine allosteric
enhancers displayed differing effects on the affinity and effi-
cacy of Cl-IB-MECA at the A3 receptor (Gao et al., 2011). In a
related study, with the intention of overcoming the issues
associated with the orthosteric antagonism shown by the
3-(2-pyridinyl)isoquinolines, a series of ring opened imidazo-
quinolinamines were synthesized to afford a range of 2,4-
disubstituted quinolines as a new class of allosteric enhancers
at the A3 receptor (Heitman et al., 2009). Rewardingly, the
best compound (LUF6096) was not only able to allosterically
enhance the binding of Cl-IB-MECA to a similar level as
LUF6000 but it also displayed negligible orthosteric affinity
for any of the adenosine receptor subtypes. These compounds
have begun to be used in mechanistic studies to identify the
basis of these allosteric effects on efficacy and affinity and the
extent to which these two effects are related.
Mechanistic insights from single-cell
ligand-binding kinetics
Allosteric interactions are a mode of communication between
distal binding sites. Intra- and intermolecular GPCR alloster-
ism with transmembrane proteins and allosteric small mol-
ecules can generate a unique spectrum of resting and/or
active distribution of GPCR conformations, which, in turn,
can significantly influence the pharmacology of orthosteric
and/or allosteric ligands. Typically, GPCR allosterism changes
the properties of conformationally linked binding sites and
therefore the association and/or dissociation kinetics of the
cognate orthosteric ligands (May et al., 2007; Smith and
Milligan, 2010). Orthosteric ligand affinity is described by the
ratio of the association to dissociation rates, and as such, an
allosteric interaction that alters orthosteric ligand affinity
does so by mediating a change in one or both of these param-
eters. Dissociation kinetic assays can be used as a powerful
mechanism to validate an allosteric mechanism of action of a
ligand since orthosteric and allosteric ligands must interact
with the receptor simultaneously to change the dissociation
kinetics of a labelled orthosteric ligand. Plotting the dissocia-
tion rate of labelled orthosteric ligand in the presence of
Figure 2
A selection of adenosine receptor allosteric modulators.
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a range of interacting ligand concentrations provides a
concentration–response relationship of a purely allosteric
effect (Kostenis and Mohr, 1996). Furthermore, the midpoint
of this curve provides an estimate of affinity of the orthosteric
ligand for the allosteric modulator occupied receptor.
Typically, dissociation kinetic studies investigating intra-
molecular allosterism use isotopic dilution. That is, the influ-
ence of an allosteric ligand on the dissociation kinetics of an
orthosteric radiolabelled probe is assessed in the presence
of a saturating concentration of a second competitive
orthosteric ligand (Bruns and Fergus, 1990a; Ellis et al., 1991;
Lee and el-Fakahany, 1991; Lazareno and Birdsall, 1995;
Christopoulos et al., 1997; Gao et al., 2001; Avlani et al., 2004;
Dowling and Charlton, 2006). A key assumption required for
interpreting such dissociation kinetic studies, however, is that
the second ligand does not alter the rate of radioligand disso-
ciation. This assumption is consistent within a theoretical
framework describing competitive interactions between com-
pounds at a monomeric receptor; however, more complex
interactions resulting from multistep ligand binding
(Swaminath et al., 2004; Ilien et al., 2009) or receptor dimeri-
zation (Christopoulos and Kenakin, 2002; Springael et al.,
2006; Han et al., 2009; May et al., 2011) could lead to a change
in the radioligand dissociation rate. Recently, the binding
kinetics of a fluorescent adenosine derivative was determined
in the absence and presence of allosteric modulators at the
adenosine A1 and A3 receptor in live single cells (May et al.,
2010b). Importantly, these studies were performed using a
closed perfusion system that enabled rapid removal of free
ligand (May et al., 2010a) and therefore assessed the dissocia-
tion kinetics under ‘infinite dilution’ conditions in the
absence of a saturating concentration of competitive orthos-
teric ligand. Similar to the previous studies, which used
isotopic dilution to promote orthosteric radioligand dissocia-
tion, PD 81,723 significantly retarded the dissociation of the
fluorescent adenosine derivate from the adenosine A1 receptor
(May et al., 2010b). In contrast, VUF5455, which has previ-
ously been demonstrated to decrease the rate of agonist dis-
sociation from the adenosine A3 receptor (Gao et al., 2001),
was found to significantly enhance the fluorescent agonist
dissociation rate (May et al., 2010b). This discrepancy may
reflect the different orthosteric agonist probes used in the
different studies and therefore the ability of allosteric modu-
lators to be highly probe-dependent (May et al., 2007). Alter-
natively, the difference could reflect a more complex receptor
arrangement than a non-interacting monomer, that is, a
dimer or higher order oligomer (see below).
Traditionally, GPCRs have been considered to exist and
function as monomeric proteins. However, it is now known
that GPCRs can form homodimers, heterodimers and/or
higher order oligomers (Smith and Milligan, 2010). Non-
visual GPCRs can be classified into three families, A–C.
Family C GPCRs are known to function as obligate dimers
(May et al., 2007; Smith and Milligan, 2010). In contrast, the
extent, stability and physiological consequence of dimeriza-
tion remains highly controversial for family A GPCRs, which
are the largest family and include the well-characterized
adrenoceptors, dopamine receptors, adenosine receptors and
muscarinic ACh receptors (Smith and Milligan, 2010). Mono-
meric family A GPCRs reconstituted in high-density lipopro-
tein phospholipid bilayer particles can couple to G proteins,
suggesting that this family does not need to function as
obligate dimers (Kuszak et al., 2009). However, evidence sug-
gests that cell surface complexes of family A GPCRs may
display a distinct profile of functional properties relative to
their monomeric counterparts. For example, dimerization
and/or oligomerization may influence signal transduction
efficiency, receptor desensitization and/or the ligand prefer-
ence for coupling to particular downstream signalling cas-
cades (May et al., 2007; Smith and Milligan, 2010; Franco
et al., 2013). Furthermore, a recent study provided evidence
for communication between simultaneously bound orthos-
teric sites on homodimeric dopamine D2 receptors (Urizar
et al., 2011). As such, a ligand bound to one protomer can
modulate ligand function and/or affinity at a second inter-
acting protomer. This may lead to complex pharmacology
and/or the potential for dimeric species to elicit specific sig-
nalling events with unique pharmacological properties.
The fundamental premise of intra- and intermolecular
allosteric modulation is based on conformational rearrange-
ments; therefore, a wealth of information can be gained
through assessing ligand-binding kinetics under different
conditions. Dissociation kinetic studies provided the first
evidence for homodimerization of a family A GPCR, the
β-adrenergic receptor. This study used an ‘infinite dilution’
approach to detect a change in the dissociation kinetics of
the radiolabelled orthosteric ligand, [3H](-)alprenolol, in
the absence and presence of unlabelled (-)alprenolol. The
increased dissociation rate in the presence of unlabelled
orthosteric ligand, (-)alprenolol, was suggestive of negatively
cooperative interactions across a β-adrenergic homodimeric
interface (Limbird et al., 1975). Intermolecular cooperativity
between orthosteric binding sites has since been established
for a number of additional GPCRs, including adenosine and
muscarinic ACh receptor subtypes (Briddon et al., 2008;
Casadó et al., 2010; Hern et al., 2010; Pisterzi et al., 2010; Hu
et al., 2012; May et al., 2011). At the adenosine A1 and
A3receptors, dissociation kinetic analysis has been employed
as a powerful method to detect intermolecular allosterism,
that is, cooperative interactions across a homodimeric inter-
face (May et al., 2011). In contrast to the adenosine A1 recep-
tor, highly cooperative interactions were observed under
‘infinite dilution’ conditions between the fluorescent adeno-
sine derivative and orthosteric agonists and antagonists at the
adenosine A3 receptor. Figure 3 shows an example of the
effect of increasing concentrations of the endogenous orthos-
teric ligand adenosine on the dissociation kinetics of a fluo-
rescent adenosine analogue from the human adenosine A3
receptor. In marked contrast, adenosine had a much less
marked effect on the dissociation kinetics of the fluorescent
ligand from the human adenosine A1 receptor (May et al.,
2011). Importantly, the intermolecular allosterism was sig-
nificantly decreased upon co-expression of a non-binding
adenosine A3-receptor mutant, supporting the suggestion of
cooperative interactions across the dimeric interface of cell
surface adenosine A3 receptors (May et al., 2011). These
studies add strength to the suggestion that the discrepancy
observed between the influence of the allosteric modulator,
VUF5455, in dissociation kinetic studies using isotopic dilu-
tion as compared to infinite dilution may reflect the ability of
adenosine A3 receptors to form interacting homodimers
and/or higher order oligomers. In keeping with this hypoth-
BJPAllosterism at adenosine A1 and A3 receptors
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esis, if a non-fluorescent orthosteric ligand (e.g. MRS1220)
is added simultaneously with a derivative of VUF5455
(VUF5645), then this allosteric compound then produces a
slowing down of the dissociation kinetics of the fluorescent
adenosine analogue (Figure 4).
Impact of A1- and A3-receptor
allosteric modulators on
in vivo pharmacology
Adenosine A1- and A3-receptor ligands (both agonists and
antagonists) have been developed for a number of potential
therapeutic indications (Muller and Jacobson, 2011). These
are summarized in Table 1. The best developed indications
appear to be for agonists where A1-receptor agonism may
have utility in angina, neuropathic pain, paroxysmal
supraventricular tachycardia and ischaemia (Griffin et al.,
2003; Morrison et al., 2006; Albrecht-Kupper et al., 2012;
Tendera et al., 2012), and A3-receptor agonists may have
benefit in liver cancer, rheumatoid arthritis, autoimmune
inflammatory disease, dry eye and cardiac ischaemia (Table 1;
Bar-Yehuda et al., 2011; Cohen et al., 2011; Fishman et al.,
2012). With regard to cancer, it is interesting that A3 receptors
appear to be overexpressed in certain cancers (e.g. breast and
colon cancer) compared to normal cells (Gessi et al., 2004;
Madi et al., 2004; Bar-Yehuda et al., 2008; Fishman et al.,
2012).
Studies with genetically altered mice have also suggested
a role of A1 receptors in pain (Sowa et al., 2010) and ischaemia
(Matherne et al., 1997) and for A3 receptors in cardiac ischae-
mia (Ge et al., 2006) and mast cell degranulation (Salvatore
et al., 2000). In the latter case, it is worth pointing out that
functional A3 receptors appear to be absent from human
mast cells (Fredholm et al., 2011). However, although selec-
tive A3-receptor activation is cardio-protective in wild-type
mice and those overexpressing the A1 receptor, adenosine
A3-receptor gene deletion generates an ischaemia-tolerant
phenotype that might be indicative of compensatory changes
(Harrison et al., 2002).
As mentioned in the introductory remarks, the ubiqui-
tous distribution of adenosine receptors and the potential for
serious side effects via the target receptor in a different organ
or cell type can limit their utility. For example, in many
non-cardiac therapeutic applications of A1-receptor agonists,
the potential for major side effects due to A1-receptor actions
in the heart will be seriously limiting. This may be particu-
larly true in the case of adenosine A1-receptor agonists that
may have potential utility in the treatment of CNS diseases,
such as epilepsy (Mares, 2010; Klaft et al., 2012). This has led
to the development of partial agonists (e.g. capadenoson;
Albrecht-Kupper et al., 2012; Tendera et al., 2012) that may
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Adenosine mediates a significant enhancement in the dissociation of 30 nM ABA-X-BY630 from the human adenosine A3 receptor. (A) Dissociation
of a fluorescent adenosine analogue, ABA-X-BY630 (30 nM), from CHO-A3 cells in the absence or presence of adenosine (1 μM; 10 μM; 100 μM).
(B) Concentration dependence of the changes in koff of 30 nM ABA-X-BY630 from CHO-A3 cells in the absence and presence of adenosine. Data
points are expressed as mean ± SEM from 3–11 separate experiments; each replicate represents the average fluorescence at the plasma membrane
of 10 individual cells. Data taken from May et al. (2011).
Figure 4
The influence of the competitive antagonist, MRS1220, and/or the
allosteric ligand, VUF5645, on the dissociation kinetics of the fluo-
rescent adenosine derivative, ABA-X-BY630. ABA-X-BY630 (30 nM)
dissociation in the absence and presence of a 1 μM MRS1220, 1 μM
VUF5645, or 1 μM MRS1220 and 1 μM VUF5645. Representative
data performed in duplicate; each replicate represent the average
fluorescence at the plasma membrane of 10 individual cells.
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have less severe off-target profiles and are less prone to recep-
tor desensitization. The potential to overcome these limita-
tions with allosteric enhancers is obvious, particularly if the
advantages offered by instilling bias into the final signalling
outcome can be exploited (as a consequence of the allosteric
impact of partner receptor-interacting proteins). However,
although in vitro studies have provided convincing evidence
for allosteric mechanisms of action for a number of ligands,
therapeutic application of these mechanisms relies on their
successful translation into whole animal physiology. Indeed,
the in vivo actions of allosteric regulators have not been
extensively investigated and there is a need to evaluate the
potential for these small molecules to augment specific
actions of adenosine in particular organs and cell types in a
whole animal setting.
Some success has been achieved in vivo with two allosteric
ligands. Adenosine receptor activation has been implicated in
the mechanism of ischaemic pre-conditioning (Carr et al.,
1997; Uematsu et al., 1998). Ischaemic pre-conditioning is
where an organ (normally the heart) is subjected to brief
periods of ischaemia and reperfusion, resulting in a resistance
to infarction. For example, in human atrial muscle, both
adenosine A1- and A3-receptor activation can mimic ischae-
mic pre-conditioning (Carr et al., 1997). Activation of adeno-
sine A1 receptors has been shown to protect against renal
ischaemia/reperfusion injury (Lee and Emala, 2000; Lee et al.,
2004). However, extra-renal side effects (e.g. bradycardia,
hypotension) may limit the use of A1-receptor agonist
therapy for acute ischaemic kidney injury (Park et al., 2012).
Interestingly, the A1-receptor allosteric enhancer PD 81,723
produced a dose-dependent protection against ischaemia/
reperfusion injury in the kidneys of wild-type mice but not in
adenosine A1-receptor-deficient mice (Park et al., 2012). This
was achieved in the absence of significant effects on heart rate
and BP, which suggests that renal A1-receptor selectivity had
been achieved with PD 81,723 as a consequence of amplify-
ing the restricted increase in adenosine in the kidney follow-
ing local ischaemia (Park et al., 2012). A similar outcome has
been reported in the CNS where administration of PD 81,723
can lead to a reduction in hippocampal injury following
hyperglycaemic ischaemia in the rat (Meno et al., 2003).
A positive allosteric modulator of the adenosine A3 recep-
tor (LUF6096) has also been shown to have benefit in an in
vivo model of myocardial ischaemia/reperfusion injury in the
dog (Du et al., 2012). Thus, LUF6096 had no effect on base-
line haemodynamic parameters, but pre-treatment with
LUF6096 prior to coronary occlusion and during reperfusion
produced a marked reduction in infarct size (ca. 50% reduc-
tion; Du et al., 2012). An equivalent reduction in the infarct
size could also be demonstrated if LUF6096 was administered
immediately before reperfusion (Du et al., 2012). These
studies collectively indicate that allosteric enhancers of the
adenosine A1 and A3 receptors may have great utility as thera-
peutic strategies to provide selective augmentation of the
actions of adenosine released locally in conditions of disease
and stress.
Concluding remarks
It is clear that allosteric mechanisms of action provide unique
ways to regulate receptor function at a local level to ‘fine-
tune’ intracellular signalling. This can be achieved by small
molecules (allosteric regulators) or by protein–protein inter-
actions involving signalling proteins (leading to biased
signalling) or oligomeric partners (e.g. as a consequence
dimerization). In all cases, these mechanisms provide the
potential to exploit the unique pharmacology provided by
allosterism to achieve both better cell and tissue selectivity of
drug treatments and also interventions with more physiologi-
cally relevant kinetic profiles. Novel fluorescent techniques
have been able to unravel some of the intricacies involved at
the single cell level. However, the therapeutic potential of
these actions awaits the clear demonstration of these mecha-
nisms in an in vivo setting.
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Table 1
Therapeutic indications for selective A1 and A3 adenosine receptor ligands
Adenosine
receptor
Changes following genetic deficit
or overexpression Potential therapeutic indications Example drugs
A1 Analgesic effects of adenosine abolished
in A1-KO mice. Overexpression of
cardiac A1 receptors caused increased
resistance to ischaemia.
Agonist Atrial fibrillation, angina,
hyperlipidaemia, neuropathic pain,
paroxysmal supraventricular
tachycardia, cardiac ischaemia
Capadenoson, Tecadenoson,
RPR749, GR79236
Antagonist Acute renal failure, heart failure (renal
function)
FK-453, SLC320
A3 Enhanced antigen-stimulated mast cell
degranulation by A3-agonists lost in
A3-KO mice. Studies with congenic
A3-/- mice indicate a cadioprotective
effect of A3-receptor activation.
Agonist Liver cancer, rheumatoid arthritis,
autoimmune inflammatory disease,
dry eye, cardiac ischaemia, dry eye
Cl-IB-MECA (CF102)
MRS3558 (CF502)
IB-MECA (CF101)
Antagonist Asthma, glaucoma KF26777, OT-7999
KO, knockout.
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